Evidence map›Paper›PMID 41221813›Full record

ArticlePharmaceutical statistics

Great Wall: A Generalized Dose Optimization Design for Drug Combination Trials Maximizing Survival Benefit.

Yan Han, Yingjie Qiu, Yi Zhao, Isabella Wan, Lang Li, Suyu Liu, Yong Zang

Abstract read
In one paragraph

Article in Pharmaceutical statistics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yan HanDepartment of Biostatistics and Health Data Science, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Yingjie QiuPeter O' Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Yi ZhaoDepartment of Biostatistics and Health Data Science, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Isabella WanFaculty of Arts and Science, University of Toronto, Toronto, Ontario, Canada.
Lang LiDepartment of Biomedical Informatics, The Ohio State University, Columbus, Ohio, USA.
Suyu LiuDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Yong ZangDepartment of Biostatistics and Health Data Science, Indiana University School of Medicine, Indianapolis, Indiana, USA.ORCID 0000-0003-0572-4756

Funding

Tumor Microenvironment and Metastasis ProgramP30CA082709 · NCI · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI Sara K Quinney · 1999 to 2026
$59.3M
UT Southwestern Medical Center Simmons Comprehensive Cancer CenterP30CA142543 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI MELANIE H. COBB · 2010 to 2026
$53.7M
Indiana Clinical and Translational Sciences InstituteUM1TR004402 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · PI Sharon M Moe, Sarah Elizabeth Wiehe · 2023 to 2026
$21.6M
Use Bayesian methods to facilitate the data integration for complex clinical trialsR01GM150808 · NIGMS · INDIANA UNIVERSITY INDIANAPOLIS · PI Yong Zang · 2023 to 2026
$1.3M
An informatics bridge over the valley of death for cancer Phase I trials of drug-combination therapiesU01CA248240 · NCI · OHIO STATE UNIVERSITY · PI LI, LANG · 2021 to 2023
$1.1M
Curve-free phase I/II clinical trial designs for molecularly targeted agents and immunotherapyR21CA264257 · NCI · INDIANA UNIVERSITY INDIANAPOLIS · PI ZANG, YONG · 2021 to 2022
$277k
Indiana CTSINCATS NIH HHS UM1 TR004402NCI NIH HHS P30 CA082709NCI NIH HHS P30 CA142543NCI NIH HHS P30CA142543NCI NIH HHS R21 CA264257NCI NIH HHS U01 CA248240NCI NIH HHS U01CA248240NIGMS NIH HHS R01 GM150808Ralph W. and Grace M. Showalter Research Trust Fund
6 · The paper itself

Abstract

Most phase I-II drug-combination trial designs assume that selecting the optimal dose combination based on early outcomes will also lead to maximum long-term survival benefits. However, this assumption is often violated in many clinical studies, generally due to high rates of relapse following the initial response. To address this problem, we propose the Great Wall design, a general dose optimization design for drug-combination trials. The Great Wall design employs a "divide-and-conquer" algorithm to address the issue of partial order of toxicity and uses early outcomes to eliminate dose combinations that are excessively toxic or less efficacious. It utilizes a dose randomization approach to construct a candidate set of the promising dose combinations balancing the toxicity and early efficacy outcomes. The patients assigned to the candidate set are followed to collect the survival outcomes and the final optimal dose combination is then selected to maximize the survival benefit. The simulation studies confirm the desirable operating characteristics of the Great Wall design under various clinical settings. R codes are also provided to facilitate the application. The Great Wall design is modular and practically useful in settings where investigators plan to follow patients long enough to assess survival outcomes.

Indexed as

Clinical Trials, Phase I as TopicClinical Trials, Phase II as TopicResearch DesignAlgorithmsComputer SimulationDose-Response Relationship, DrugDrug CombinationsDrug Therapy, CombinationHumansRandomized Controlled Trials as TopicDrug Combinationsdose optimization designdose randomizationdrug‐combination trialimmunotherapyphase I–II clinical trialsurvival outcome

Identifiers

PMID41221813
PMCPMC12606548

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.